{"podcast":{"title":"Let's Talk Risk! Podcast","slug":"let-s-talk-risk-podcast-6693844","podcast_index_feed_id":6693844,"rss_url":"https://api.substack.com/feed/podcast/1477050.rss","website_url":"https://naveenagarwalphd.substack.com/podcast","image_url":"https://substackcdn.com/feed/podcast/1477050/ee2039dcd34796f25b1263b7e1659bef.jpg","author":"Where MedTech professionals gain clarity and confidence to navigate complex decisions.","episode_count":182,"summary":"Where MedTech professionals gain clarity and confidence to navigate complex risk, quality, and leadership challenges.","last_synced_at":"2026-09-12T00:18:22.009520+00:00","page_url":"https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844"},"episode":{"title":"Deep Dive: What FDA’s QMSR Warning Letters Are Revealing","slug":"deep-dive-what-fda-s-qmsr-warning-letters-are-revealing","published_at":"2026-09-11T12:00:00+00:00","page_url":"https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-what-fda-s-qmsr-warning-letters-are-revealing","show_page_url":"https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844","url":"https://naveenagarwalphd.substack.com/p/deep-dive-what-fdas-qmsr-warning-letters-are-revealing","audio_url":"https://api.substack.com/feed/podcast/215055684/1af5f4af054c7af856736dd0d75c4561.mp3","summary":"If you’re trying to manage risk in isolated silos, your quality management system is already obsolete. What happens when a supplier changes a device label without triggering design controls? When operators quietly rework nonconforming product? Or when serious post-market signals never make it back into the risk file? This Deep Dive examines recent FDA inspection and warning-letter examples through one common lens: the integration of risk management across the quality system. The cases illustrate how seemingly separate failures in supplier controls, manufacturing, complaints, nonconforming product, CAPA, and infrastructure can become connected risk-management failures under QMSR. Key highlights covered in the audio: * Why ISO 13485 Clause 7.1 is becoming so important — and how risk management increasingly connects multiple parts of the QMS. * Supplier changes can become risk-management events when labeling, intended use, or other product assumptions change without adequate escalation. * Undocumented shop-floor rework can hide risk signals , leaving management metrics looking healthy while process problems accumulate. * CAPA cannot work in isolation when environmental controls, process data, nonconformances, and risk analyses are disconnected. * A static risk file is no longer enough. Post-market experience, manufacturing changes, supplier issues, and emerging hazards must continually inform lifecycle risk management. The broader lesson is straightforward: QMSR is pushing companies away from managing compliance clause by clause and toward managing risk as an interconnected system. And that raises an important question for medical device organizations: When a new signal appears anywhere in your quality system, can it actually find its way back to the assumptions in your r…","meta_description":"If you’re trying to manage risk in isolated silos, your quality management system is already obsolete. What happens when a supplier changes a device label…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1273,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/deep-dive-what-fda-s-qmsr-warning-letters-are-revealing/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-what-fda-s-qmsr-warning-letters-are-revealing.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}